Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1281-1300 of 1,694 trials

Kidney Disease: VX-147 Study for APOL1 Variants

We are testing the safety and effectiveness of VX-147 in adults and children with APOL1-mediated proteinuric kidney disease. The study aims to see if this treatment can improve kidney function and reduce related health risks.

APOL1-mediated Proteinuric Kidney Disease>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNephrology

Chronic Lymphocytic Leukemia: APG-2575 Study

We are studying a new medication, APG-2575, for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial will evaluate its safety and effectiveness alone and with other treatments.

Chronic Lymphocytic Leukemia (CLL)1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Heart Failure: Sacubitril/Valsartan Treatment

We are studying whether the medication Sacubitril/Valsartan can improve heart function in patients with transthyretin cardiac amyloidosis and heart failure. This trial will help us understand its effects on heart pumping ability.

Transthyretin Cardiac Amyloidosis>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Colorectal Cancer: Temozolomide and Irinotecan Treatment

We are studying a combination of temozolomide and irinotecan for patients with specific colorectal cancer characteristics after standard chemotherapy. The goal is to see if this treatment helps eliminate remaining cancer cells and improves survival.

Stage II/III Colorectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Lung Cancer Treatment: Adagrasib with Pembrolizumab

We are studying whether adding Adagrasib to standard chemotherapy and Pembrolizumab helps patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The trial will also evaluate safety and quality of life.

Metastatic Non-small Cell Lung CancerConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementOncology

Plaque Psoriasis: JNJ-77242113 Study

We are assessing a new treatment for moderate to severe plaque psoriasis to see if it works better than a placebo and an existing medication. This study aims to understand its effectiveness and safety.

Plaque Psoriasis>2 yearsConfirmation phase (III)Investigational MedicinesDermatology

Functional Dyspepsia: Rikkunshito Study

We are investigating whether Rikkunshito can help relieve symptoms in patients with functional dyspepsia. The study also looks at how it may affect the digestive lining and overall gut function.

Functional Dyspepsia3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Niemann-Pick Type C and GM1/GM2 Gangliosidosis: Nizubaglustat Study

We are investigating how well nizubaglustat works and its safety for children with Niemann-Pick type C disease and GM1 or GM2 gangliosidosis. This study aims to see if it can improve movement and coordination compared to a placebo.

Niemann-Pick Type C Disease and GM1/GM2 Gangliosidoses1-2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesNeurologyPediatrics

HIV Treatment: Comparing DOR/3TC and DTG/3TC

We are studying whether a new two-drug regimen can maintain viral suppression in people living with HIV who are currently stable on a three-drug treatment. This trial will also assess various health outcomes and side effects over time.

HIV Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious Diseases

Alcohol-Associated Hepatitis: Alpha-1 Antitrypsin Treatment

We are studying whether intravenous Alpha-1 Antitrypsin can reduce inflammation in patients with severe alcohol-associated hepatitis. The trial also looks at its safety and effects on liver health.

Alcohol-Associated Hepatitis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Vemurafenib for BRAF Positive Juvenile Histiocytosis

We are studying the safety and effectiveness of vemurafenib in children with BRAF mutation-resistant histiocytosis. This trial aims to find the best dosage and treatment duration for these young patients.

Histiocytic Cell Proliferation>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Chronic Low Back Pain: Antibiotic Treatment Study

We are studying whether a three-month course of amoxicillin can help people with chronic low back pain and specific MRI changes. This trial compares the antibiotic treatment to a placebo to see if it offers any benefits.

Non-Specific Low Back Pain1-2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesInfectious DiseasesOrthopedics and Traumatology

Acute Kidney Injury: Angiotensin Receptor Blocker Study

We are studying whether an angiotensin receptor blocker can improve heart and kidney health in patients recovering from acute kidney injury after ICU discharge. This trial will help us understand its effects on overall health and safety.

Acute Kidney Injury>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyInternal MedicineNephrology

Clindamycin for Infections: Impact of Rifampicin and Obesity

We are studying how body weight and the antibiotic rifampicin affect the effectiveness of clindamycin in treating infections. This research may help improve treatment strategies for patients with varying body types.

Hidradenitis SuppurativaProsthetic Joint InfectionsFracture Related Infections≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

C3 Glomerulopathy: Aliskiren vs. Enalapril

We are studying whether the medication aliskiren can improve kidney function in people with C3 glomerulopathy compared to the standard treatment, enalapril. This trial aims to assess its safety and effectiveness in reducing kidney disease markers.

C3 Glomerulopathy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesNephrology

Histiocytosis in Children: Trametinib Study

We are testing the safety and effectiveness of trametinib in children with refractory histiocytosis. The goal is to find the best dosage and timing for treatment after other therapies have failed.

Erdheim-Chester DiseaseRosai-Dorfman SyndromeLangerhans' Cell Histiocytosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Primary Biliary Cholangitis: Golexanolone Study

We are testing a new medication, golexanolone, for individuals with primary biliary cholangitis who have significant fatigue and cognitive difficulties. The study aims to evaluate its safety and effects on daily life and cognitive function.

Primary Biliary Cholangitis3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesHepatologyInternal Medicine

Atrial Fibrillation After CABG: Anticoagulant Study

We are studying whether adding anticoagulant medications helps prevent blood clots in patients with new-onset atrial fibrillation after heart surgery. This trial aims to ensure safety and effectiveness in managing this condition.

Atrial FibrillationNew-Onset Post-Operative Atrial Fibrillation after CABG6-12 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal Medicine

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Drug-Resistant Epilepsy: Rapamycin Study

We are investigating whether rapamycin is safe and effective for people with drug-resistant epilepsy due to tuberous sclerosis complex. The study also examines its effects on related neuropsychiatric disorders and tumors.

Tuberous Sclerosis Complex3-6 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNeurology